Amazon Fire Tablet Down to $54, Rivaling the $329 iPad with This New All-Time Low Price
Amazon has already started this year's Prime Day celebrations ahead of schedule, and it unveiled special deals on its website since morning. On most of its own brand products such as Fire TV and Fire tablets, Prime members are discovering fantastic deals.
Of these, one of the standout devices is the Amazon Fire HD 8 Plus tablet and it is now available at a fresh all-time low price of $54: That's a big markdown from its regular list price of $120, and at 54% off, it's not surprising that this tablet is the #1 best-seller in the Computers category on Amazon with over 10,000 units sold alone just last month.
See at Amazon
With an 8-inch HD screen, it delivers crisp images that are great for viewing videos, reading or browsing the web. The screen is made of strengthened aluminosilicate glass that is twice as tumble-resistant as the Apple iPad mini 2021 in tumble tests. Its more compact and lightweight newest design can fit into a pocket or bag without any hassle for long periods of time.
It features a faster hexa-core processor that's 30% faster than the previous generation along with 3GB of RAM for effortless multitasking. Whether you're reading mail, checking your to-do lists or jumping between apps, this tablet catches up without sacrificing a step. The 32GB storage is ample for most people and if you need more space, expandable storage is an option to 1TB via the microSD card.
The Fire HD 8 Plus also supports wireless charging: Just put the tablet onto a compatible wireless charging dock (separately available) and it charges up without any fuss. That makes it perfect for use in busy homes where devices are always being used and need to be topped up in a hurry. The tablet is also supplied with a 9W charger in the box for ordinary charging.
It also offers up to 13 hours of total usage including reading, web browsing, video streaming and listening to music. That gives you the capacity to hear or view your favorite content throughout the day without concern about juice exhaustion. Fire HD 8 Plus comes with a preinstalled 2MP front-facing camera and 5MP rear camera so that you can snap photos or keep in touch with friends and family using apps like Zoom. Alexa is built into it so that you can speak your way into making video calls or receiving fast answers to your questions.
For entertainment, the Fire HD 8 Plus has access to a broad array of popular apps and services, including Netflix, Facebook, Hulu, Instagram, and TikTok. While the Amazon Appstore is not compatible with Google Play, there's still a great assortment of available options to keep everyone entertained. Some do have subscription requirements, but there's no lack of free content to enjoy.
Don't wait too long, though: limited-time deals like this one tend to disappear very rapidly as soon as Prime Day officially begins.
See at Amazon
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Ongoing phase 2 study evaluating riliprubart for the potential prevention and treatment of active antibody-mediated rejection in kidney transplant recipients Riliprubart was also designated orphan drug for the investigational use in chronic inflammatory demyelinating polyneuropathy in the US and EU Paris, June 25, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to riliprubart for the investigational treatment of antibody-mediated rejection (AMR) in solid organ transplantation. This designation reflects Sanofi's commitment to addressing a critical unmet need in transplant medicine, where AMR remains a significant challenge with no FDA-approved treatments available. The FDA grants orphan drug designation to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the US. Global Therapeutic Area Development Head, Immunology and Inflammation, Sanofi"Orphan drug designation for riliprubart marks an important milestone in our mission to address critical challenges in transplant medicine leveraging our expertise in immunology. Antibody mediated rejection represents a serious threat to transplanted organs and patient survival. Through riliprubart's innovative mechanism of action, we hope to bring forward a treatment option that could significantly improve outcomes for kidney transplant recipients." Riliprubart is currently being explored in multiple clinical studies across different indications in transplant and neurology. A phase 2 clinical study is currently ongoing, exploring its potential in kidney transplant recipients (NCT05156710). The study includes two patient cohorts: those at risk of developing rejection and those with active forms of antibody-mediated rejection. In addition, Sanofi is conducting two phase 3 studies exploring riliprubart in chronic inflammatory demyelinating polyneuropathy (CIPD), a rare neurological disorder, specifically in patients refractory to standard of care (MOBILIZE, clinical study identifier: NCT06290128), and in IVIg-treated patients (VITALIZE, clinical study identifier: NCT06290141). The broad clinical development program for riliprubart emphasizes Sanofi's commitment to exploring riliprubart's potential across multiple immune-mediated conditions with high unmet medical needs. About Riliprubart SAR445088 (riliprubart) is a potential first-in-class, IgG4 humanized monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway of the innate immune system. Riliprubart is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority. For more information on riliprubart clinical studies, please visit About AMRAntibody-mediated rejection is a serious complication that may arise after solid organ transplantation, occurring when the recipient's immune system produces antibodies that attack the transplanted organ. Sensitized recipients, who have pre-existing antibodies that target foreign antigens including those found on transplanted organs, face a high risk of developing antibody-mediated rejection. Subsequent immune response can lead to inflammation, organ damage, and organ failure if left untreated. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Evan Berland | +1 215 432 0234 | Léo Le Bourhis | +33 6 75 06 43 81 | Victor Rouault | +33 6 70 93 71 40 | Timothy Gilbert | +1 516 521 2929 | Léa Ubaldi | +33 6 30 19 66 46 | Investor RelationsThomas Kudsk Larsen | +44 7545 513 693 | Alizé Kaisserian | +33 6 47 04 12 11 | Felix Lauscher | +1 908 612 7239 | Keita Browne | +1 781 249 1766 | Nathalie Pham | +33 7 85 93 30 17 | Tarik Elgoutni | +1 617 710 3587 | Thibaud Châtelet | +33 6 80 80 89 90 | Yun Li | +33 6 84 00 90 72 | Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group. Attachment Press Release
Yahoo
17 minutes ago
- Yahoo
Truist Lowers GitLab (GTLB) PT to $75, Maintains Buy Rating
GitLab Inc. (NASDAQ:) is one of the best technology stocks according to Wall Street analysts. Earlier on June 12, Truist adjusted the price target for GitLab to $75 from $80, while maintaining a Buy rating on the shares. This revision comes after GitLab's Q1 2025 results, which, although exceeding guidance, did not meet investor expectations for a larger beat. In Q1, the company reported a total revenue of $169.2 million, which marked a 33% increase year-over-year. GitLab also generated positive cash flow for the first time in a first quarter. The subscription revenue from self-managed and SaaS grew to $151.179 million from $111.191 million year-over-year, and license revenue from self-managed and other increased to $18.008 million from $15.687 million. A team of software engineers working together in an open office, developing innovative solutions. The company's customer base also expanded, with customers contributing over $5,000 of ARR, reaching 8,976, which showed a 21% increase year-over-year. Customers with over $100,000 of ARR grew by 35% year-over-year, totaling 1,025. In this quarter, GitLab also received the 2024 Google Cloud Technology Partner of the Year Award in the Application Development – DevOps category. GitLab Inc. (NASDAQ:GTLB) develops software for the software development lifecycle in the US, Europe, and the Asia Pacific. While we acknowledge the potential of GTLB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Target Just Raised Its Dividend. Should You Buy TGT Stock Here?
Dividend season may be winding down, but a few heavyweight names are still stepping up with headline-worthy hikes. Retail giant Target (TGT) recently bumped its quarterly dividend by 1.8% to $1.14 per share, marking its 54th consecutive year of dividend growth and cementing its title as a 'Dividend Aristocrat' — those elite S&P 500 Index ($SPX) names with more than 25 years of uninterrupted hikes. In a market where even legacy firms are slashing payouts, this kind of consistency signals resilience that investors crave. But make no mistake, this is not the golden age of retail. Tariffs, margin pressure, and shifting consumer values have complicated the game. Target has been caught in the middle — its DEI moves triggered backlash, its assortment fell out of sync with shopper moods, and its once-shining Ulta (ULTA) partnership hit pause. First-quarter earnings undershot expectations, leaving analysts split on how fast a turnaround can come. Still, the company is recalibrating. This New ETF Promises to Help You Invest Like Warren Buffett and Yields 15% 3 Dirt-Cheap Dividend Aristocrats About to Explode Higher Buy These 3 High-Yield Dividend Stocks for Portfolio Protection Amid Israel-Iran Conflict Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. With shares down double digits in 2025 but a fresh dividend hike signaling confidence, could this be the sweet spot for long-term investors to scoop up TGT stock before the next turnaround kicks in? Target has come a long way from its brick-and-mortar roots. Once known simply as a big-box chain, it's now a full-fledged omnichannel force, blending sleek stores with rapid digital fulfillment, thanks in part to its Shipt acquisition. With a market capitalization of $43.8 billion and nearly 2,000 U.S. stores, Target thrives across categories — from essentials to electronics, fashion to toys. Its owned brands, curated partnerships, and upgraded in-store experiences make it a retail standout in both convenience and style. Shares of Target have stumbled 34% over the past 52 weeks, weighed down by weak earnings, fading foot traffic, tariff uncertainty, and consumer backlash. Although TGT stock has rebounded more than 11% from its April low of $87.35, investors remain cautious, eyeing a turnaround that's still more promise than proof in a retail landscape demanding speed and precision. In terms of valuation, the stock is trading at 12.7 times forward earnings and 0.41 times sales. That's lower than both Target's industry peers and its own five-year average multiples. While markets wobble, Target holds steady, rocking its 'Dividend King' crown and paying up like royalty to loyal shareholders. The latest dividend boost extends its streak to over five decades of annual hikes. The new dividend will be paid on Sept. 1, offering a healthy 4.64% annual yield. That's well above the S&P 500 SPDR's (SPY) 1.19% and outshines the S&P Retail SPDR's (XRT) yield of 1.39%, enhancing its appeal to income-focused investors. Plus, in Q1 alone, Target returned $510 million to shareholders, edging past last year's $508 million. With a disciplined payout ratio of 54.5%, Target is dependable, having a rare blend of income, history, and sustainability in the retail sector. On May 21, Target reported disappointing Q1 earnings results, missing on both revenue and earnings, sending the stock tumbling 5%. The retail giant continues to grapple with soft consumer demand, pricing pressures, and operational inefficiencies, all of which weighed heavily on its performance and forced a downward revision to its full-year guidance. Target's adjusted EPS declined 36% year-over-year (YOY) to $1.30, missing estimates by nearly 20%. Total revenue fell 2.8% annually to $23.8 billion, with merchandise sales down 3.1% to $23.4 billion. Comparable sales declined 3.8%, hurt by a 5.7% drop in in-store traffic and a 2.4% decrease in total transactions. Digital sales, however, were a bright spot, rising 4.7%. That was thanks in part to a 36% jump in same-day delivery through Target Circle 360 and successful brand collaborations. Margins came under pressure, with gross margin narrowing to 28.2%, largely due to heavy markdowns and rising digital fulfillment and supply-chain costs. Adjusted operating margin dropped to 3.7%. Inventory swelled 11% annually as well, a clear sign of sluggish sales and ongoing misalignment between consumer demand and stock planning. Despite ending the quarter with $2.9 billion in cash, Target faces mounting pressure. CFO Jim Lee acknowledged the 'highly challenging' backdrop, citing prolonged weakness in consumer confidence, uncertainty around tariffs, and fallout from the company's revised DEI stance. In response, Target unveiled a new Enterprise Acceleration Office focused on agility, innovation, and AI-driven efficiency. Yet, despite these ambitious efforts, the company trimmed its full-year adjusted EPS forecast to between $7 and $9, down from the previous $8.80 to $9.80 range. Target also estimates a low single-digit sales decline, signaling a prolonged road ahead for recovery. Analysts tracking Target predict its profit to decline by 15% to $7.51 per share in fiscal 2025, before bouncing back with a 7.5% rebound to $8.07 in 2026. Target has a consensus 'Moderate Buy' rating overall. Out of the 34 analysts offering recommendations for the stock, eight analysts recommend a 'Strong Buy,' three analysts advise a 'Moderate Buy,' 21 suggest a 'Hold' rating, and the remaining two have 'Strong Sell' ratings. Meanwhile, the mean price target of $110.62 suggests upside potential of 12%. The Street-high target of $175 implies the stock could rally as much as 79%. Target's journey has never been smooth. But from the 2008 crash to the pandemic to today's retail unrest, the company hasn't flinched where it matters — its cash discipline. While some others cut back, Target has continued returning capital to shareholders. That kind of loyalty does not come without strong fundamentals. Through decades of disruption, Target's consistency in rewarding investors is a signal that, even in storms, this ship knows how to sail. For investors, it's a test of patience. Target may be bruised, but its dividend track record suggests the story is far from over. On the date of publication, Sristi Suman Jayaswal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
